Defining the Antimalarial Activity of Cipargamin in Healthy Volunteers Experimentally Infected with Blood-Stage Plasmodium falciparum

The spiroindolone cipargamin, a new antimalarial compound that inhibits Plasmodium ATP4, is currently in clinical development. This study aimed to characterize the antimalarial activity of cipargamin in healthy volunteers experimentally infected with blood-stage Plasmodium falciparum. Eight subjects...

Descripción completa

Detalles Bibliográficos
Autores principales: McCarthy, James S., Abd-Rahman, Azrin N., Collins, Katharine A., Marquart, Louise, Griffin, Paul, Kümmel, Anne, Fuchs, Aline, Winnips, Cornelis, Mishra, Vishal, Csermak-Renner, Katalin, Jain, J. Prakash, Gandhi, Preetam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2021
Materias:
Clinical Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849011/
https://www.ncbi.nlm.nih.gov/pubmed/33199389
http://dx.doi.org/10.1128/AAC.01423-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849011/
https://www.ncbi.nlm.nih.gov/pubmed/33199389
http://dx.doi.org/10.1128/AAC.01423-20

Ejemplares similares